Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial

Abstract

Background

Contrary to strong recommendations for high-dose intravenous corticosteroid treatment for relapses in multiple sclerosis (MS), uncertainty remains about most aspects of relapse management. Oral corticosteroids administered by physicians or patients themselves or no corticosteroids also appear justifiable.

Objective

To evaluate an education program that aims to involve patients with MS in decisions on relapse management.

Methods

In three German MS centers, 150 patients with relapsing MS were randomly assigned to a single, 4-h group session or a standard information leaflet. The primary outcome measure was the proportion of relapses with oral or no corticosteroid therapy as an indicator of patient autonomy in treatment decision making. Other outcomes included perceived decision autonomy, quality of life, and disability status.

Results

In the intervention group (IG), 108/139 (78%) relapses were treated with oral or no corticosteroids compared with 101/179 (56%) in the control group; P < 0.0001. Patients’ perceived autonomy of treatment decision making was significantly higher in the IG; P < 0.0001. Quality of life, disability status, and adverse events of corticosteroid therapies were comparable.

Conclusion

The patient education program led to more autonomous decision making in patients with relapsing MS. Relevant changes in relapse management were observed.

Keywords

decision making decision support technique glucocorticoids multiple sclerosis patient education patient participation

Get full access to this article

View all access options for this article.

References

1 Weinshenker BG Bass B Rice GP . The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419–1428.

2 Liu C Blumhardt LD . Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better. Mult Scler 1999; 5: 22–28.

3 Richards RG Sampson FC Beard SM Tappenden P . A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6: 1–73.

4 Young PJ Lederer C Eder K . Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006; 67: 804–808.

5 Confavreux C Vukusic S Moreau T Adeleine P . Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438.

6 Goodin DS Frohman EM Garmany GP . Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169–178.

7 Rieckmann P . Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Immunmodulatorische Stufentherapie der Multiplen Sklerose: Aktuelle Therapieempfehlungen (September 2006). [Escalating immunomodulatory therapy of multiple sclerosis: Update (September 2006).] Nervenarzt 2006; 77: 1506–1518.

9 Tremlett HL Luscombe DK Wiles CM . Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998; 65: 362–365.

10.

10 Filippini G Brusaferri F Sibley WA . Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (4): CD001331.

11.

11 Köpke S Heesen C Kasper J Mühlhauser I . Steroid treatment for relapses in multiple sclerosis – the evidence urges shared decision-making. Acta Neurol Scand 2004; 110: 1–5.

12.

12 Sellebjerg F Frederiksen JL Nielsen PM Olesen J . Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529–534.

13.

13 Kasper J Köpke S Mühlhauser I Heesen C . Evidence-based patient information about treatment of multiple sclerosis—a phase one study on comprehension and emotional responses. Patient Educ Couns 2006; 62: 56–63.

14.

14 Whitney SN McGuire AL McCullough LB . A typology of shared decision making, informed consent, and simple consent. Ann Intern Med 2004; 140: 54–59.

15.

15 Towle A Godolphin W . Framework for teaching and learning informed shared decision making. BMJ 1999; 319: 766–771.

16.

16 Heesen C Kasper J Segal J Köpke S Mühlhauser I . Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. Mult Scler 2004; 10: 643–650.

17.

17 Vickrey BG Shatin D Wolf SM . Management of multiple sclerosis across managed care and fee-for-service systems. Neurology 2000; 55: 1341–1349.

18.

18 Steckelberg A Berger B Köpke S Heesen C Mühlhauser I . Kriterien für evidenzbasierte Patienteninformationen. [Criteria for evidence-based patient information] Z Arztl Fortbild Qualitatssich 2005; 99: 343–351.

19.

19 Rogers R . A protection motivation theory of fear appeals and attitude change. J Psychol 1975; 91: 93–114.

20.

20 Boer H Seydel ER . Protection motivation theory. In: M Connor P Norman , (eds), Predicting health behavior. Buckingham: Open University Press; 1996; 20: 95–120.

21.

21 Meyer H . Unterichtsmethoden [Teaching methods]. Frankfurt: Cornelsen Scriptor; 1983.

22.

22 Köpke S; . Entwicklung eines Schulungsprogramms und Evaluationskonzepts zur Kortisonbehandlung im akuten Schub der Multiplen Sklerose [Development of an educational programme and evaluation concept for corticoid treatment in acute relapses of multiple sclerosis]. Hamburg: University of Hamburg; 2003 (state examination thesis).

23.

23 Entwistle VA Skea ZC O’Donnell MT . Decisions about treatment: interpretations of two measures of control by women having a hysterectomy. Soc Sci Med 2001; 53: 721–732.

24.

24 Gold SM Heesen C Schulz H . Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001; 7: 119–130.

25.

25 Sharrack B Hughes RA . The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999; 5: 223–233.

26.

26 Heesen C Reich C Borchers C Gold SM Schulz KH . Patientenbasierte Scoringsysteme bei Multipler Sklerose – Untersuchung zur Validierung der United Kingdom Disability Scale (UNDS) und des Patient-Generated-Index (PGI). [Patient based scoring instruments in multiple sclerosis – German validation of the United Kingdom Disability Scale (UNDS) and the Patient-Generated-Index (PGI)] Neurol Rehabil 2007; 13: 17–29.

27.

27 Newcombe RG . Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998; 17: 2635–2650.

28.

28 Mohr DC Hart SL Julian L Cox D Pelletier D . Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004; 328: 731–733.

29.

29 Campbell M Fitzpatrick R Haines A . Framework for design and evaluation of complex interventions to improve health. BMJ 2000; 321: 694–696.

30.

30 Lenz M Steckelberg A Richter B Mühlhauser I . Meta-analysis does not allow appraisal of complex interventions in diabetes and hypertension self-management: a methodological review. Diabetologia 2007; 50: 1375–1383.

31.

31 Bekker H Thornton JG Airey CM . Informed decision making: an annotated bibliography and systematic review. Health Technol Assess 1999; 3: 1–156.

32.

32 Kasper J Burisch G Geiger F Heesen C . Do patients perceive the involvement we observe? (abstract). In: Härter, M, Simon, D, Loh, A (eds), 4th International Shared Decision Making Conference. Lengerich: Pabst; 2007; 32: 147.

33.

33 Elwyn G O’Connor A Stacey D . Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006; 333: 417–419.

34.

34 Newman S Steed L Mulligan K . Self-management interventions for chronic illness. Lancet 2004; 364: 1523–1537.